Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

35.64USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$35.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,410,941
52-wk High
$47.81
52-wk Low
$29.44

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 31.22 30.93 32.76
EPS (TTM): 1.23 -- --
ROI: 2.39 15.07 14.61
ROE: 5.71 16.60 16.34

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

17 Jul 2018

Mylan signs U.S. license deal on Humira with AbbVie

July 17 AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition.

17 Jul 2018

BUZZ-India's Dr.Reddy's Laboratories plunges; Indivior wins preliminary injunction against co

** Dr.Reddy's Laboratories Ltd falls as much as 10.8 pct to a five-week low of 2,069.95 rupees

16 Jul 2018

BUZZ-India's Dr.Reddy's rises on US drug hopes; UK rival Indivior cuts guidance

** Dr.Reddy's Laboratories Ltd rise as much as 3.8 pct to 2,387.65 rupees, its highest in 3 weeks

12 Jul 2018

Indivior says 2018 profit to fall short after U.S. market hit

British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.

11 Jul 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

Indivior gets breather after court extends order blocking generic rival

Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.

29 Jun 2018

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

14 Jun 2018

UPDATE 2-FDA finds deficiencies in Mylan's generic Advair; shares fall

* Shares fall 4.5 pct after market (Adds analyst comment; updates shares)

14 Jun 2018

FDA finds deficiencies in Mylan's generic Advair

June 13 U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version.

14 Jun 2018

Earnings vs. Estimates